Your browser is no longer supported. Please, upgrade your browser.
Tarsus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own6.00% Shs Outstand20.34M Perf Week-12.89%
Market Cap460.20M Forward P/E- EPS next Y-5.57 Insider Trans-36.65% Shs Float14.64M Perf Month-22.12%
Income- PEG- EPS next Q-0.48 Inst Own62.40% Short Float2.23% Perf Quarter-26.53%
Sales33.43M P/S13.77 EPS this Y-425.30% Inst Trans0.09% Short Ratio4.63 Perf Half Y-40.13%
Book/sh9.01 P/B2.50 EPS next Y-380.20% ROA- Target Price- Perf Year-
Cash/sh7.66 P/C2.95 EPS next 5Y- ROE- 52W Range15.32 - 63.69 Perf YTD-45.39%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.56% Beta-
Dividend %- Quick Ratio18.90 Sales past 5Y- Gross Margin- 52W Low47.28% ATR1.57
Employees20 Current Ratio18.90 Sales Q/Q- Oper. Margin- RSI (14)27.62 Volatility7.96% 5.64%
OptionableNo Debt/Eq0.00 EPS Q/Q289.40% Profit Margin- Rel Volume0.25 Prev Close22.77
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume70.69K Price22.57
Recom1.20 SMA20-14.94% SMA50-25.42% SMA200-29.01% Volume17,655 Change-0.88%
Nov-10-20Initiated Raymond James Strong Buy $39
Nov-10-20Initiated Ladenburg Thalmann Buy $42
Nov-10-20Initiated Jefferies Buy $35
Nov-10-20Initiated BofA Securities Buy $33
Jul-24-21 06:00PM  
Jul-20-21 08:37AM  
Jul-07-21 04:05PM  
Jun-26-21 07:34AM  
Jun-22-21 06:00AM  
Jun-21-21 12:52PM  
Jun-18-21 04:05PM  
Jun-16-21 04:05PM  
May-24-21 04:05PM  
May-11-21 04:05PM  
May-04-21 04:05PM  
May-03-21 04:08PM  
Apr-27-21 04:05PM  
Apr-20-21 09:09AM  
Mar-31-21 04:05PM  
Mar-30-21 07:14AM  
Mar-29-21 04:05PM  
Jan-19-21 08:30AM  
Jan-18-21 08:43AM  
Jan-07-21 09:24AM  
Jan-05-21 05:00PM  
Dec-23-20 07:00AM  
Dec-21-20 07:00AM  
Nov-19-20 03:24PM  
Nov-13-20 07:35PM  
Oct-20-20 04:05PM  
Oct-16-20 06:05PM  
Oct-15-20 08:35PM  
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vivo Capital IX, LLC10% OwnerJun 25Sale29.607,704228,0382,987,331Jun 25 09:30 PM
Vivo Capital IX, LLC10% OwnerJun 24Sale29.9010,000299,0002,995,035Jun 25 09:30 PM
Vivo Capital IX, LLC10% OwnerJun 23Sale29.8037,9801,131,8043,005,035Jun 25 09:30 PM
Vivo Capital IX, LLC10% OwnerJun 22Sale28.50110,0003,135,0003,043,015Jun 25 08:51 PM
Vivo Capital IX, LLC10% OwnerJun 21Sale29.7091,6202,721,1143,153,015Jun 25 08:51 PM
RTW INVESTMENTS, LP10% OwnerMay 07Sale29.98450,00013,491,0002,013,601May 07 08:01 PM
Vivo Capital IX, LLC10% OwnerApr 14Sale30.3740012,1483,244,635Apr 16 09:07 PM